Carbubarb
Clinical data | |
---|---|
Trade names | Nogexan |
Other names | Carbubarbital |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number |
|
PubChem CID | |
ChemSpider |
|
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C11H17N3O5 |
Molar mass | 271.273 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
NY (what is this?) (verify) |
Carbubarb (Carbubarbital, trade name Nogexan) is a carbamate-substituted barbiturate derivative, which has sedative effects.[1]
References
- ↑ US patent 4428887, Tou, J. S. & Schleppnik, A. A., "Method of producing mono-substituted terminal diesters", issued 1984-01-31, assigned to Monsanto
Alcohols |
|
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents |
|
Monoureides |
|
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.